Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Other financing activities (2016 - 2024)

Ani Pharmaceuticals' Other financing activities history spans 10 years, with the latest figure at $2.0 million for Q4 2024.

  • For Q4 2024, Other financing activities changed N/A year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, changed 0.0%, while the annual FY2024 figure was $17.4 million, N/A changed from the prior year.
  • Other financing activities for Q4 2024 was $2.0 million at Ani Pharmaceuticals, up from -$3000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $2.0 million in Q4 2024 and bottomed at -$3000.0 in Q2 2022.
  • The 4-year median for Other financing activities is $281000.0 (2020), against an average of $568111.1.
  • The largest annual shift saw Other financing activities soared 180.42% in 2021 before it tumbled 100.89% in 2022.
  • A 4-year view of Other financing activities shows it stood at $618000.0 in 2020, then surged by 180.42% to $1.7 million in 2021, then plummeted by 100.17% to -$3000.0 in 2022, then skyrocketed by 66000.0% to $2.0 million in 2024.
  • Per Business Quant, the three most recent readings for ANIP's Other financing activities are $2.0 million (Q4 2024), -$3000.0 (Q2 2022), and $3000.0 (Q1 2022).